Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Cancer

Interventions

BIOLOGICAL: Patritumab deruxtecan

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]